23.Shore ND.Mantz CA.Dosoretz DE.Fernandez E.Myslicki FA.McCov C.Finkelstein Se.Fishman MN Cancer Control.20(1): 24.Scott AM,Wolchok JD,Old LJ(March 2012)."Antibody therapy of cancer Nature Reviews.Cancer (/pubmed/22437872) 5.rding.().The immunogenicity of humanized ww.ncbi.nl m. 8 icle/PMC2881252)8.PMID204008610 ncbi.nlm.nih.gov/) wang s spMcssoeeehtfornm for cancer 兰品尚益恩 120022 27.Seide Schlege Lang P(2013)."Natural killer cell mediated antibody-dependent cellular ov/pmc/a gov/pm ynchi nlm nib dbt10339fmmu2013.0076atps-/oog/10.3389%2 Pfimmmu.2013.0076 diated c 5815854PMD1503604m w.ncbi.nlm.nih.gov/pubmed/15036044).doi:10.1016/j.it.2004.01.008(hutps:/doi.org/10.1016%2Fj.it.200 4.01,008 s J.Keegan P.Pazdu 20081DA for B-cellchronic leukemia The.13 ww.ncbi.nlm.nih pubr d/18305062007.0218 nt for bladde g/. /Newsroo m/Pres m50 762.htm).FI May 2016.20 M 31 b).Retr ed approval /fda-ipilimuma 32.Lemery SJ,Zhang J,Rothmann MD,Yang J,Earp J,Zhao H.McDougal A,Pilaro A,Chiang R. eegan P,Paz 010 Food and Drug Administratio and alemtuzumab"Clinical cancer res 0h.6:488PMD2060146d www.ncbi nlm 8060146.dot:10.1581078-0432.CCR-10.0570hps/doL0g10.i58%2F1078-0 33c P (April 2015)"The f 24R6201-56 61.PMID 25838373(https://www.ncbi.nlm.nih.gov/pubmed/25838373).doi:10.1126/science.aaa8172(ht tps:/doiorg/10.1126%2F aa8172 Administration".AIDS Treatment News (284):2-3.PMID 11364912 (hutps:/www.ncbi.nlm.nih.gov/pub med11364912） MD.Khandelwa Pazdur R (201"U.S.Food and drug administration app atminbaninnXegaB cyclophosphamide for the /pmc/arti pD21212432 chi nlm n )06honcost1-3(ps:d.0oc 3620 for Dru valumab (mfinzi)"(ht ovdrugs/informationondrugs/approveddruscms5m)gov Retrieved 201 37.Byrd oCroatcoehoetcekemahp/2oawasetagatombok.orgc